CN106727500A - The application of dihydroartemisinine, suppression medicine and its application - Google Patents
The application of dihydroartemisinine, suppression medicine and its application Download PDFInfo
- Publication number
- CN106727500A CN106727500A CN201710023981.5A CN201710023981A CN106727500A CN 106727500 A CN106727500 A CN 106727500A CN 201710023981 A CN201710023981 A CN 201710023981A CN 106727500 A CN106727500 A CN 106727500A
- Authority
- CN
- China
- Prior art keywords
- dha
- stat3
- medicine
- application
- dihydroartemisinine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application of dihydroartemisinine, suppression medicine and its application.The present invention relates to a kind of application of antimalarial agent-dihydroartemisinine (DHA) in signal transduction and activating transcription factor (STAT3) abnormal activation medicine is suppressed.Found by experiment in vivo and in vitro, DHA can Selective depression STAT3 phosphorylation activation, this inflammatory factor IL 6 that acts on stimulates, can also play under low-oxygen environment.Suppression STAT3 abnormal activation medicines containing DHA, can be used to treat the diseases related to STAT3 abnormal activations such as tumour, autoimmune disease and diseases associated with inflammation.
Description
Technical field
The invention belongs to field of medicaments, and in particular to antimalarial agent-dihydroartemisinine (DHA) is suppressing STAT3 abnormal activations
Application in medicine.Meanwhile, the invention further relates to a kind of suppression medicine containing the dihydroartemisinine, and the suppression medicine
Using.
Background technology
DHA is the important derivatives and main active of antimalarial Chinese medicine qinghaosu, and its drug effect is that other artemisines spread out
Biological 3~5 times.DHA and qinghaosu are slaughtered cry of a deer professor and find and thereby is achieved the Nuo Bei of 2015 by famous pharmacy man
The prize of your physiological medical science, both have been used for treating various malaria and especially pernicious malaria, resistance malaria and encephalic malaria and obtain
Good result, it is considered to be the first-line drug for the treatment of malaria.In vivo, after qinghaosu and its derivative rapidly transform into DHA
Competence exertion antimalarial active, the peroxide bond in molecular structure is the key point that DHA eliminates plasmodium.In liver and gall tubule
Interior, then DHA enters small enteral by UDP-glucoronosyl/transferase glucuronic acid through choledochus, is followed by multiple liver sausage
Ring is excreted eventually through urine and excrement.Its characteristic distributions is concentration highest in spleen, is secondly kidney, adrenal gland and liver
It is dirty.Research finds, except antimalarial and anti-schistosomiasis, DHA also has regulation inflammatory reaction, improves lupus erythematosus, antibacterial and disease-resistant
The multiple drug effect such as poison.
Numerous researchs have confirmed, STAT3 (Signal transducers and activators of
Transcription 3, STAT3) to tumour generation development have important facilitation.Under physiological status, the STAT3 of monomer
It is in cytoplasm and inactive, it is necessary to phosphorylation activation play effect.STAT3 molecules have Tyr 705 and Ser 727 two
Phosphorylation activation site, Tyr 705 is STAT3 dimerizations, nuclear translocation and the critical sites for combining DNA;Ser 727 is then
ERK1/2 and JNK etc. activates the site of STAT3.Jak2, EGFR and SRC etc. pass through acceptor/non-receptor activation pathway activation monomer
STAT3, dimerization forms homologous or heterodimer, into karyon in specific target gene combination activated transcription, regulate and control downstream
The expression of albumen.In normal structure, the activation of STAT3 is rapid and of short duration, and in tumour cell, STAT3 is then persistently activated.Swash
STAT3 living not only promotes normal cell canceration, Tumor Angiongesis and cancer cell migration, and maintains breast cancer and incidence
" stem cell " characteristic of the tumor stem cells such as tumour cell (HNSCC).Lung cancer, liver cancer, head and neck scale carcinoma, breast cancer, prostate cancer
Expression high, activation STAT3 is found that with leukaemia etc., its incidence is more than 50% in liver cancer, lung cancer and breast cancer,
And then it is up to more than 95% in HNSCC cells.Numerous result of study promptings, the activation of STAT3 is the required of normal cell canceration
Condition, is the requirement for maintaining tumour cell and its stem cell properties, is the requirement for maintaining tumor cell proliferation growth,
It is the requirement of some other oncogene activation.Additionally, STAT3 produces radiation and chemotherapy to resist tumour cell also important
Facilitation, can reverse this chemicotherapy to resist if it being blocked with inhibitor or Decoy oligonucleotides and is activated.
Many factors can activate STAT3, such as SRC, EGFR, IL-6, IL-10, CXCL12 and COX-2 albumen and the factor
STAT3 can be directly or indirectly activated, and in environment such as hypoxemia, can equally activate STAT3.Because STAT3 is many signals
The joint of path and shared signal protein, therefore, except tumour, it is also closely related with various diseases.The inflammation such as IL-6 because
Son activation STAT3 release pyrogens influence immunocyte and then cause acute inflammation.STAT3 can Targeted-control blood vessel endothelium
The expression of growth factor (VEGF), therefore its generation development to heart and vascular diseases has a major impact, and be dilatancy cardiac muscle
The necessary condition that disease progression is aggravated.Research it has also been found that, STAT3 activation after can with the clinical symptoms of heavy system lupus erythematosus,
And aggravate rheumatoid arthritis inflammation performance, cause the exacerbation of the state of an illness.Additionally, the oneself state of STAT3 also with Crow grace
Disease is relevant with the generation of ulcerative colitis, and promotes ulcerative colitis to change to malignant tumour.
STAT3 is by sustained activation in tumour cell and inflammatory tissue, blocked can reverse disease generation development and
Lapse to.At present, the activation that various directly or indirectly inhibitor block STAT3 is had been developed for.Direct inhibitor include Stattic,
S3I-1757 and BP-1-102 etc., such inhibitor is combined with STAT3 molecules, is allowed to that activation function can not be played;Suppress indirectly
Agent then suppresses STAT3 activation, AG490, AZD1480, Cucurbitacin B and turmeric indirectly by regulating and controlling the albumen such as SRC, EGFR and Jak2
Element etc. belongs to indirect inhibitor.Although the above-mentioned significant anticancer effect of inhibitor, due to stability, water-soluble and toxic and side effect
Etc. reason, only only a few inhibitor is used for zoopery and clinical experimental study.
The content of the invention
It is an object of the present invention to provide a kind of antimalarial common drug-dihydroartemisinine (Dihydroartemisinin, DHA)
Application in STAT3 abnormal activations are suppressed.
Dihydroartemisinine is used to suppress STAT3 abnormal activations, and the molecular formula of the dihydroartemisinine is as follows:
Other STAT3 inhibitor are compared, the DHA from plant can synthesize on a large scale, and medicine cost is relatively
It is low, it is very helpful to reducing medical expense and medical burden, the economy of raising drug therapy.
DHA clinically using for a long time, is clearly slapped to its medicine pharmacokinetics in itself and pharmacodynamics
Hold, these clinical experiences can help select optimal drug dosage, medication cycle and administrated method etc., can greatly shorten clinical examination
The time is tested, is that other any STAT3 inhibitor can not be when.
The inhibitory action that DHA is activated to STAT3 is notable and has specificity higher, only to abnormal cell and tissue
STAT3 activation has important inhibitory action, and normal cell and tissue are affected by it very little, is conducive to the clinical toxic and side effect that reduces to carry
The tolerance level of patient high.
Further, dihydroartemisinine is used to suppress the STAT3 activation when hypoxemia or/and IL-6 protein factors stimulate.
Hypoxemia is intracellular common microenvironment, and not only in normal oxygen, Selective depression STAT3 is activated dihydroartemisinine, this
Effect can also be played under low oxygen conditions.IL-6 protein factors can directly or indirectly activate STAT3, and in environment such as hypoxemia,
STAT3 can be equally activated, dihydroartemisinine is to the inhibitory action of STAT3 abnormal activations in hypoxia condition or/and IL-6 albumen
The factor can also be played when stimulating.
One kind suppresses medicine, and the suppression medicine contains dihydroartemisinine.
Further, the suppression medicine contains drug excipient or carrier.
Further, the drug excipient or carrier include glycerine, ethanol, BS, dimethyl sulfoxide (DMSO), physiology salt
One or more in water.
Further, double blue and green artemisin concentration are 40-200 μm of ol/L in the suppression medicine.
Further, the described medicine that suppresses is used in the Disease Intervention with STAT3 abnormal activation characteristics.
Further, it is described suppress medicine be used for the Disease Intervention time with STAT3 abnormal activation characteristics >=
12h。
Further, the disease of the STAT3 abnormal activations characteristic includes tumour, autoimmune disease, inflammatory disease
Disease.
The autoimmune pathologies and diseases associated with inflammation, including ulcerative colitis, systemic loupus erythematosus, class wind
Wet arthritis, ankylosing spondylitis, idiopathic thrombocytopenic purpure, psoriasis, multiple sclerosis, chronic nephritis,
The diseases such as gastritis, pancreatitis, inflammatory lung conditions, bronchial astehma, obstructive nephropathy, the retinitis.
The tumour include liver cancer, breast cancer, cancer of pancreas, Huppert's disease, leukaemia, lymthoma, lung cancer, stomach cancer,
Cancer of the esophagus, the carcinoma of the rectum, colon cancer, cutaneum carcinoma, melanoma, prostate cancer, brain tumor and cervical carcinoma etc..
Further, the suppression medicine is used in combination with cancer therapy drug or anti-inflammatory drug.
The present invention carries out experiment in vitro first, from three kinds of representative head and neck scale carcinoma cells, using Western blotting
The technology such as (Western blotting) and plasmid transfection, it was demonstrated that DHA can suppress the activation of Jak2/STAT3 signal paths, this
Kind can also be played under acting on inflammatory factor IL-6 stimulations, low-oxygen environment.Then by itself and the most frequently used STAT3 inhibitor
AG490 and AZD1480 compare, it is found that three kinds of medicines can suppress STAT3 activation with drug concentration increase, show that DHA is one
Plant STAT3 activation inhibitors.Transplantable tumor animal model is finally set up, further proves that DHA can significantly inhibit the growth of transplantable tumor,
And the activator protein of Jak2 and STAT3 is lowered, experimental animal is without obvious toxic and side effect.The experimental result of in vitro and in vivo shows
Show, suppress Jak2/STAT3 signal activations by specificity, DHA can significantly inhibit the growth of HNSCC cells.
Brief description of the drawings
Fig. 1 is the activation of DHA suppression HNSCC cells STAT3 under normal oxygen condition.
Fig. 2 is the activation of DHA suppression HNSCC cells STAT3 under hypoxia.
Fig. 3 is that DHA suppresses HNSCC cells p-STAT3 expression with specificity.
Fig. 4 is that DHA suppresses STAT3 signal paths upstream p-Jak2 protein expressions.
Fig. 5 is Jak2 and the STAT3 activation that DHA suppresses that IL-6 causes.
Fig. 6 is DHA as a kind of new Jak2/STAT3 signal pathway inhibitors.
Fig. 7 is the activation that DHA suppresses Jak2/STAT3 signal paths in zoografting tumor tissue.
Specific embodiment
Embodiment one
DHA suppresses the activation of HNSCC cells STAT3 under normal oxygen condition.
Prepare DHA solution.DHA pulvis 1g are weighed, dimethyl sulfoxide (DMSO) (DMSO) solution 17.584ml is added, under gnotobasis
With 1ml pipettors, pressure-vaccum, by complete drug dissolution, is prepared into the DHA solution of 200mM/L repeatedly, is distributed into sterile vials, be placed in-
80 DEG C freeze standby, and the used time now matches somebody with somebody.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, after existing prepare, the culture medium 2ml containing various concentrations DHA of addition after cell attachment.Medicine is done
The μ l of RAPI lysates 100 are added to extract cell protein after terminating in advance.Tumor tissue protein extraction:Tumor tissue is taken out from liquid nitrogen, will
It inserts homogenizer homogenate after being cut into tiny fragment, adds RIPA lysates of the 500 μ l containing PMSF, and 30min is placed on ice, cracks
During repeatedly homogenate grinding thoroughly cracking histocyte.Then by Tissue Lysates move into centrifuge tube in, under the conditions of 4 DEG C,
12000rpm is centrifuged 15min, and Aspirate supernatant is placed in liquid nitrogen and saves backup.Using BCA standard measure protein concentrations, calculate and carry
The protein concentration of each sample for taking, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen, then carries out albuminous degeneration.Match somebody with somebody
The separation gel of system 8~12%, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% and concentrates glue, insert comb.Treat glue
Comb is extracted after condensation, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen Marker as control, connects electricity
Stream, carries out SDS-PAGE electrophoresis, time about 2h.Filter paper, pvdf membrane, gel are sequentially placed into after end, both positive and negative polarity is noted, electricity is poured into
Turn liquid, by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then 1h is closed and with containing primary antibody with skimmed milk power
Skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, is developed using ECL methods.
DHA suppresses the activation of HNSCC cells STAT3 under normal oxygen condition.Three kinds of tumour cells Fadu, Hep-2, Cal-27 are used
DHA intervenes 24h, Fadu DHA concentration be 0,20,40,80,160 μm of ol/L, Hep-2 and Cal-27 DHA concentration be 0,10,
20、40、80μmol/L;Or the DHA of doses acts on three kinds of cancer cells, and Fadu DHA concentration is 160 μm of ol/L, Hep-2
With Cal-27 with DHA concentration be 80 μm of ol/L, with Western blotting detect 0,6h, 12h, 24h and 48h when p-STAT3
Expression.Result is as shown in Figure 1:P-STAT3 in tumour cell subtracts with the increase of DHA concentration and intervention time
Few, control group is without significant change.This explanation, DHA substantially suppresses the activation of STAT3, and is closed in dependence with dosage and time is intervened
System.
Embodiment two
DHA suppresses the activation of HNSCC cells STAT3 under hypoxia.
Hypoxemia is microenvironment common in malignant cell, and tumor cell proliferation, invasion and attack, transfer and generation can be promoted to put
Chemoresistance, therefore the Synergistic action of research DHA is significant under low oxygen conditions.
Prepare DHA solution.DHA pulvis 1g are weighed, dimethyl sulfoxide (DMSO) DMSO solution 10.284ml, ethanol solution is added
7.3ml, with 1ml pipettors, pressure-vaccum, by complete drug dissolution, is prepared into the DHA solution of 200mM/L repeatedly under gnotobasis, packing
Enter sterile vials, be placed in -80 DEG C and freeze standby, the used time now matches somebody with somebody.
Hypoxemia device and hypoxia condition.Hypoxemia equipment in microbiological incubator is home-made contrivance, and hypoxemia device is by six pieces
The poly (methyl methacrylate) plate bonding of thick 8mm is formed, and is divided into room and lid two parts, has the pipe of control gas turnover respectively in the both sides of room
Road, air intake duct covers and pads last layer soft rubber pad, with anti-gas-leak, tighten fixation near bottom, gas off-take near top in closing
Screw, it is ensured that anoxic case is completely closed.The hypoxemia Related Experimental Study that my laboratory is carried out in the past can confirm that the device is used for
Study the feasibility of hypoxemia.This experiment hypoxia condition is 37 DEG C, 5%CO2, 1%O2, 94%N2.Institute in charge flow rate and container
Zirconia oxygen analyzer is determined aerobic partial pressure reaching standard time again.Gaseous mixture (95%N is passed through by air intake duct2, 5%CO2), while beating
Feed channel is outputed, draft speed is 3L/min, after ventilation 8min, then to being passed through (1%O in hypoxemia device2, 94%N2, 5%CO2)
Gaseous mixture, draft speed is 3L/min, after ventilation 5min, in case oxygen concentration change by zirconia oxygen analyzer monitored over time, most
The whole low oxygen concentration for needed for experiment.When partial pressure of oxygen is up to standard in hypoxemia device, draft speed is changed to low-flow ventilation 0.8L/min,
To maintain oxygen concentration in low-oxygen box, to ensure the stabilization of oxygen concentration in low-oxygen box.Obtained by the gaseous mixture for preparing different oxygen
Corresponding low oxygen concentration, this model error it is minimum (<0.02) low oxygen concentration of stabilization, can especially be obtained.This model is convenient
It is easy, the need for various different hypoxics researchs can be met.In addition, this modelling economy, simple to operate, horizontal high voltage can be entered
Sterilizing etc. is disinfected, easy to utilize.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, after existing prepare, the culture medium 2ml containing various concentrations DHA of addition after cell attachment.Medicine is done
The μ l of RAPI lysates 100 are added to extract cell protein after terminating in advance.Tumor tissue protein extraction:Tumor tissue is taken out from liquid nitrogen, will
It inserts homogenizer homogenate after being cut into tiny fragment, adds RIPA lysates of the 500 μ l containing PMSF, and 30min is placed on ice, cracks
During repeatedly homogenate grinding thoroughly cracking histocyte.Then by Tissue Lysates move into centrifuge tube in, under the conditions of 4 DEG C,
12000rpm is centrifuged 15min, and Aspirate supernatant is placed in liquid nitrogen and saves backup.Using BCA standard measure protein concentrations, calculate and carry
The protein concentration of each sample for taking, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen, then carries out albuminous degeneration.Match somebody with somebody
The separation gel of system 8~12%, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% and concentrates glue, insert comb.Treat glue
Comb is extracted after condensation, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen Marker as control, connects electricity
Stream, carries out SDS-PAGE electrophoresis, time about 2h.Filter paper, pvdf membrane, gel are sequentially placed into after end, both positive and negative polarity is noted, electricity is poured into
Turn liquid, by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then 1h is closed and with containing primary antibody with skimmed milk power
Skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, is developed using ECL methods.
The condition of this experimental selection hypoxemia is 1%O2, DHA intervention tri- kinds of HNSCC cell 24h of Fadu, Hep-2, Cal-27,
It is that 160 μm of ol/L, Cal-27 and Hep-2 DHA intervene concentration for 80 μm of ol/L that Fadu DHA intervene concentration.Result such as Fig. 2 institutes
Show, p-STAT3 protein expressions are still subject to substantially suppression, and (to add relative medicine or hypoxemia treatment, "-" is addition solvent pair to "+"
According to Actin is albumen internal reference).Therefore, under low-oxygen environment, DHA can also suppress the activation of STAT3 albumen.
Embodiment three
DHA suppresses HNSCC cells p-STAT3 expression has specificity.
Prepare DHA solution.DHA pulvis 1g are weighed, glycerine 10.584ml, BS 7ml is added, used under gnotobasis
Pressure-vaccum, by complete drug dissolution, is prepared into the DHA solution of 200mM/L to 1ml pipettors repeatedly, is distributed into sterile vials, is placed in -80
DEG C freeze standby, the used time now matches somebody with somebody.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, after existing prepare, the culture medium 2ml containing various concentrations DHA of addition after cell attachment.Medicine is done
The μ l of RAPI lysates 100 are added to extract cell protein after terminating in advance.Tumor tissue protein extraction:Tumor tissue is taken out from liquid nitrogen, will
It inserts homogenizer homogenate after being cut into tiny fragment, adds RIPA lysates of the 500 μ l containing PMSF, and 30min is placed on ice, cracks
During repeatedly homogenate grinding thoroughly cracking histocyte.Then by Tissue Lysates move into centrifuge tube in, under the conditions of 4 DEG C,
12000rpm is centrifuged 15min, and Aspirate supernatant is placed in liquid nitrogen and saves backup.Using BCA standard measure protein concentrations, calculate and carry
The protein concentration of each sample for taking, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen, then carries out albuminous degeneration.Match somebody with somebody
The separation gel of system 8~12%, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% and concentrates glue, insert comb.Treat glue
Comb is extracted after condensation, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen Marker as control, connects electricity
Stream, carries out SDS-PAGE electrophoresis, time about 2h.Filter paper, pvdf membrane, gel are sequentially placed into after end, both positive and negative polarity is noted, electricity is poured into
Turn liquid, by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then 1h is closed and with containing primary antibody with skimmed milk power
Skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, is developed using ECL methods.
Three kinds of tumour cells Fadu, Hep-2, Cal-27 with DHA intervene 24h, Fadu with DHA concentration be 0,20,40,80,
160 μm of ol/L, Hep-2 and Cal-27 are 0,10,20,40,80 μm of ol/L with DHA concentration, as a result as shown in figure 3, p-STAT3 is bright
It is aobvious to be suppressed, and p-Erk1/2 and p-Akt albumen is without significant change.
Example IV
DHA suppresses STAT3 signal paths upstream p-Jak2 protein expressions.
Prepare DHA solution.DHA pulvis 1g are weighed, glycerine 7.584ml, physiological saline 10ml is added, used under gnotobasis
Pressure-vaccum, by complete drug dissolution, is prepared into the DHA solution of 200mM/L to 1ml pipettors repeatedly, is distributed into sterile vials, is placed in -80
DEG C freeze standby, the used time now matches somebody with somebody.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, after existing prepare, the culture medium 2ml containing various concentrations DHA of addition after cell attachment.Medicine is done
The μ l of RAPI lysates 100 are added to extract cell protein after terminating in advance.Tumor tissue protein extraction:Tumor tissue is taken out from liquid nitrogen, will
It inserts homogenizer homogenate after being cut into tiny fragment, adds RIPA lysates of the 500 μ l containing PMSF, and 30min is placed on ice, cracks
During repeatedly homogenate grinding thoroughly cracking histocyte.Then by Tissue Lysates move into centrifuge tube in, under the conditions of 4 DEG C,
12000rpm is centrifuged 15min, and Aspirate supernatant is placed in liquid nitrogen and saves backup.Using BCA standard measure protein concentrations, calculate and carry
The protein concentration of each sample for taking, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen, then carries out albuminous degeneration.Match somebody with somebody
The separation gel of system 8~12%, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% and concentrates glue, insert comb.Treat glue
Comb is extracted after condensation, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen Marker as control, connects electricity
Stream, carries out SDS-PAGE electrophoresis, time about 2h.Filter paper, pvdf membrane, gel are sequentially placed into after end, both positive and negative polarity is noted, electricity is poured into
Turn liquid, by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then 1h is closed and with containing primary antibody with skimmed milk power
Skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, is developed using ECL methods.
Three kinds of tumour cells Fadu, Hep-2, Cal-27 with DHA intervene 24h, Fadu with DHA concentration be 0,20,40,80,
160 μm of ol/L, Hep-2 and Cal-27 DHA concentration are 0,10,20,40,80 μm of ol/L, observe p-EGFR, p-Jak2, p-SRC
And p-STAT3 protein expression situations.Result such as Fig. 4 point out, three kinds of tumour cell p-Jak2 and p-STAT3 protein expressions with
The increase of DHA dosage and decline, and two kinds of albumen of p-EGFR and p-SRC then without substantially change.
Embodiment five
DHA suppresses Jak2 and the STAT3 activation that IL-6 causes.
Prepare DHA solution.Weigh DHA pulvis 1g, add dimethyl sulfoxide (DMSO) DMSO solution 6.584ml, glycerine 11ml is aseptic
With 1ml pipettors, pressure-vaccum, by complete drug dissolution, is prepared into the DHA solution of 200mM/L repeatedly under environment, is distributed into aseptic small
Bottle, is placed in -80 DEG C and freezes standby, and the used time now matches somebody with somebody.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, after existing prepare, the culture medium 2ml containing various concentrations DHA of addition after cell attachment.Medicine is done
The μ l of RAPI lysates 100 are added to extract cell protein after terminating in advance.Tumor tissue protein extraction:Tumor tissue is taken out from liquid nitrogen, will
It inserts homogenizer homogenate after being cut into tiny fragment, adds RIPA lysates of the 500 μ l containing PMSF, and 30min is placed on ice, cracks
During repeatedly homogenate grinding thoroughly cracking histocyte.Then by Tissue Lysates move into centrifuge tube in, under the conditions of 4 DEG C,
12000rpm is centrifuged 15min, and Aspirate supernatant is placed in liquid nitrogen and saves backup.Using BCA standard measure protein concentrations, calculate and carry
The protein concentration of each sample for taking, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen, then carries out albuminous degeneration.Match somebody with somebody
The separation gel of system 8~12%, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% and concentrates glue, insert comb.Treat glue
Comb is extracted after condensation, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen Marker as control, connects electricity
Stream, carries out SDS-PAGE electrophoresis, time about 2h.Filter paper, pvdf membrane, gel are sequentially placed into after end, both positive and negative polarity is noted, electricity is poured into
Turn liquid, by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then 1h is closed and with containing primary antibody with skimmed milk power
Skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, is developed using ECL methods.
Fadu DHA concentration is that 160 μm of ol/L, Hep-2 and Cal-27 DHA concentration are 80 μm of ol/L, and DHA intervenes 24h
Afterwards, (to add relative medicine treatment, "-" is addition solvent control to "+", and Actin is to add people to recombinate IL-6 (20ng) interventions 1h
Albumen internal reference).Result such as Fig. 5 is pointed out, and IL-6 can be such that p-Jak2 the and p-STAT3 protein expressions in three kinds of cancer cells substantially increase
Plus, and DHA then significantly reduces two kinds of albumen.
Embodiment six
DHA can be used as a kind of new Jak2/STAT3 signal pathway inhibitors.
Prepare DHA solution.DHA pulvis 1g are weighed, ethanol 17.584ml is added, under gnotobasis with 1ml pipettors repeatedly
Complete drug dissolution is prepared into the DHA solution of 200mM/L by pressure-vaccum, is distributed into sterile vials, and AZD1480 and AG490 are
The dimethyl sulfoxide (DMSO) DMSO solution of 100mM/L concentration, three kinds of medicines are placed in -80 DEG C and freeze standby, and the used time now matches somebody with somebody.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, and intervention experiment is distinguished after DHA, AZD1480 and AG490 of various concentrations is used after cell attachment
Three kinds of squamous cell carcinomas.Pharmaceutical intervention adds the μ l of RAPI lysates 100 to extract cell protein after terminating.Tumor tissue protein extraction:From
Tumor tissue is taken out in liquid nitrogen, homogenizer homogenate is inserted after being cut into tiny fragment, add RIPAs of the 500 μ l containing PMSF to crack
Liquid, places 30min on ice, and homogenate grinding thoroughly cracks histocyte repeatedly in cracking process.Then Tissue Lysates are moved into
In centrifuge tube, under the conditions of 4 DEG C, 12000rpm centrifugation 15min, Aspirate supernatant is placed in liquid nitrogen and saves backup.It is legal using BCA
Amount protein concentration, calculates the protein concentration of each sample of extraction, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen,
Then carry out albuminous degeneration.8~12% separation gel is prepared, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% dense
Contracting glue, inserts comb.Wait comb is extracted after the knot that is gelled, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen
Marker carries out SDS-PAGE electrophoresis, time about 2h as control, turn-on current.Be sequentially placed into after end filter paper, pvdf membrane,
Gel, notes both positive and negative polarity, pours into electricity and turns liquid, and by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then degreasing is used
Milk powder closing 1h and with contain primary antibody skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, uses
ECL methods are developed.
AZD1480 and AG490 are two kinds of STAT3 signal path specific inhibitors, and this part is studied first by both medicines
Fadu, Cal-27 and Hep-2 cell 24h are intervened with different dosage, it is suppressed then to observe three kinds of tumor cell activities with mtt assay
Situation processed, the corresponding IC50 values of AZD1480 and AG490 are calculated according to its result.Determine two kinds of inhibitor further according to IC50 values
Intervention concentration (with reference to the selection of DHA concentration, i.e. maximum dose more than IC50 values, and its residual value is less than IC50 values, and concentration gradient is again
Than setting).After inhibitor concentration setting, three kinds of squamous carcinomas of intervention experiment are distinguished with DHA, AZD1480 and AG490 of various concentrations
Cell 24h.The expression of p-Jak2 and p-STAT3 albumen declines with the concentration of Experimental agents.This result as shown in fig. 6,
It is similar to specific STAT3 inhibitor AZD1480 and AG490 effect, DHA equally can substantially suppress head and neck scale carcinoma cell Jak2 and
The activation of STAT3 albumen.And, in same concentration, DHA presses down compared with AG490 to Hep-2 Carbazole alkaloids to two kinds of albumen of activation
System is more notable.
Embodiment seven
DHA suppresses the activation of Jak2/STAT3 signal paths in zoografting tumor tissue.
Prepare DHA solution.DHA pulvis 1g are weighed, ethanol 9.584ml, physiological saline 8ml is added, 1ml is used under gnotobasis
Pressure-vaccum, by complete drug dissolution, is prepared into the DHA solution of 200mM/L to pipettor repeatedly, is distributed into sterile vials, is placed in -80 DEG C
Freeze standby, the used time now matches somebody with somebody.
The raising of BALb/c male nude mouses and the foundation of Transplanted tumor model.14 BALb/c male nude mouses (4~6 weeks, 18~
20g weights), to raise in Bethune International Peace Hospital's Experimental Animal Center (SPF grades), receptacle is at 24 DEG C of constant temperature and sound insulation
Reason, the daily light and shade time is 12/12h, and lamina air flow filtering, aseptic feed and aqua sterilisa freely eat for animal, and animal is raised
Support in cage, most 5 animals of each cage, regularly replace bedding and padding.Nude mice reaches Experimental Animal Center and raises 1 week, treats that it is adapted to
After new environment and observation animal ordinary circumstance is good, the Cal-27 cells of exponential phase are collected in digestion, after counting that its is dense
It is condensed to 5 × 107The unicellular solution of/ml Hanks, by every 0.2ml be inoculated in left side groin on the outside of it is subcutaneous, be successfully established shifting
Plant knurl animal model.Zoopery is whole to be carried out under the supervision and accreditation of Ethics Committee of Bethune International Peace Hospital.
Animal packet and DHA intervene:Transplanted tumor in nude mice diameter it is long to 5mm or so when be grouped with random table, i.e. DHA groups and control group
(n=7).DHA groups give 50mg/kg, and control group then gives DMSO, and two groups of animals are administered using intraperitoneal injection, continuous note
Penetrate 2/3 day and rest 1 day, inject 5 times weekly, intervention time amounts to 28 days.The measurement of transplantable tumor volume and the weight of animals:See daily
Examine the ordinary circumstances such as the animal state of mind, diet and defecation, pay special attention to whether there is bite, tumor by local skin whether there is ulceration etc..
With gross tumor volume of electronics vernier caliper measurement, while electronic scale claims the weight of animals, register and statistical measurement number within every 4 days
According to noticing control group and experimental group body weight whether there is significant difference.Gross tumor volume is calculated with below equation:Volume (cm3)=
It is wide2(cm2) × long (cm)/2.After last time DHA intraperitoneal injections 24h, CO is first used2Anesthetized animal, then uses at disconnected neck method
Dead experiment nude mice.The transplanting tumor tissue for stripping is divided into two parts, and a part is placed in paraformaldehyde solution for immunohistochemistry
Dyeing;Another part is placed in liquid nitrogen is used for Western blot analysis Jak2/STAT3 signal paths GAP-associated protein GAP changes.
Cell immunohistochemical staining method.Animal tumor tissue sample presses 4 μ m thick serial section, is then attached to rely through poly
On the slide of propylhomoserin treatment, 60 DEG C overnight.Will dewaxing 20min 2 times in section dimethylbenzene;It is dipped in 100% ethanol 2min 2
It is secondary;95% ethanol 2min 2 times;90% ethanol 2min 3 times;85% ethanol 2min 2 times;75% ethanol 2min 2 times.Will section
It is placed in citric acid reparation liquid, in heating in pressure cooker;Pressure cooker stops heating after boiling 2~3min, is then down to room temperature, uses
PBS washing slice 5min, totally 3 times.The activity that 3% hydrogen peroxide closes peroxidase is added dropwise, then 5min3 is washed with PBS
It is secondary, lowlenthal serum room temperature closing 20min is added dropwise.P-Jak2 (Tyr1007/1008) and p-STAT3 (Tyr705) primary antibody is added dropwise, presses
1:100 dilution proportions, overnight incubation in 4 DEG C of refrigerators.With PBS washing slices 5min 3 times, goat antirabbit secondary antibody is added dropwise, room temperature is incubated
20min is educated, then 5min is washed with PBS 3 times.In horseradish enzyme mark strepto- avidin working solution is added dropwise in section, 37 DEG C are incubated
20min, PBS washing 5min 3 times.Colour developing is controlled with DAB under microscope, is cut into slices with running water cleaning down.Haematoxylin redyeing
3min, 1% hydrochloride alcohol differentiation, ammoniacal liquor returns indigo plant, gradient alcohol dehydration, each 2min, xylene soak 5min2 times, neutral tree
Glue mounting.The positive and negative tissue of DHA experimental groups and DMSO control groups mutually using 400 × microphotograph preservation.
Western blotting detect DHA to HNSCC cellular associated proteins expressions.The extraction of cell protein:Choosing
Take the logarithm growth period Fadu, Cal-27 and Hep-2 head and neck scale carcinoma cell, digestion count after with 4 × 105/ 2ml/well cells are close
Degree is inoculated into 6 well culture plates, after existing prepare, the culture medium 2ml containing various concentrations DHA of addition after cell attachment.Medicine is done
The μ l of RAPI lysates 100 are added to extract cell protein after terminating in advance.Tumor tissue protein extraction:Tumor tissue is taken out from liquid nitrogen, will
It inserts homogenizer homogenate after being cut into tiny fragment, adds RIPA lysates of the 500 μ l containing PMSF, and 30min is placed on ice, cracks
During repeatedly homogenate grinding thoroughly cracking histocyte.Then by Tissue Lysates move into centrifuge tube in, under the conditions of 4 DEG C,
12000rpm is centrifuged 15min, and Aspirate supernatant is placed in liquid nitrogen and saves backup.Using BCA standard measure protein concentrations, calculate and carry
The protein concentration of each sample for taking, is distributed into the centrifuge tubes of 200 μ 1, and often pipe contains 40 μ g albumen, then carries out albuminous degeneration.Match somebody with somebody
The separation gel of system 8~12%, room temperature places 30min.Treat that gelling knot, in g., jelly-like, prepares 4% and concentrates glue, insert comb.Treat glue
Comb is extracted after condensation, electrophoresis liquid is poured into, injector adds protein sample and standard items albumen Marker as control, connects electricity
Stream, carries out SDS-PAGE electrophoresis, time about 2h.Filter paper, pvdf membrane, gel are sequentially placed into after end, both positive and negative polarity is noted, electricity is poured into
Turn liquid, by the albumen transferring film on separation gel to pvdf membrane, the time is about 4h.Then 1h is closed and with containing primary antibody with skimmed milk power
Skimmed milk power and 4 DEG C of overnight incubations of pvdf membrane.Next day washes film and is incubated secondary antibody 1h, is developed using ECL methods.
Fig. 7 is the activation that DHA suppresses Jak2/STAT3 signal paths in zoografting tumor tissue, is as a result shown, control group
Jak2 and STAT3 activation is expression high, and the activation of two kinds of albumen of DHA groups is significantly inhibited.
Presently preferred embodiments of the present invention is the foregoing is only, is not intended to limit the invention, it is all in essence of the invention
Within god and principle, any modification, equivalent substitution and improvements made etc. should be included within the scope of the present invention.
Claims (10)
1. a kind of application of dihydroartemisinine, it is characterised in that:The dihydroartemisinine is used to suppress STAT3 abnormal activations, institute
The molecular formula for stating dihydroartemisinine is as follows:
2. the application of dihydroartemisinine according to claim 1, it is characterised in that:
The dihydroartemisinine is used to suppress the STAT3 activation when hypoxemia or/and IL-6 protein factors stimulate.
It is 3. a kind of to suppress medicine, it is characterised in that:The suppression medicine contains dihydroartemisinine as claimed in claim 1.
4. suppression medicine according to claim 3, it is characterised in that:The suppression medicine contains drug excipient or load
Body.
5. suppression medicine according to claim 4, it is characterised in that:The drug excipient or carrier include glycerine, second
One or more in alcohol, BS, dimethyl sulfoxide (DMSO), physiological saline.
6. suppression medicine according to claim 5, it is characterised in that:Double blue and green artemisin concentration are 40-200 μm of ol/
L。
7. the application of a kind of suppression medicine as any one of claim 3 to 6, it is characterised in that:The suppression medicine
For in the Disease Intervention with STAT3 abnormal activation characteristics.
8. the application for suppressing medicine according to claim 7, it is characterised in that:The intervention time of the suppression medicine >=
12h。
9. the application for suppressing medicine according to claim 8, it is characterised in that:The disease includes tumour, autoimmunity
Property disease, diseases associated with inflammation.
10. the application for suppressing medicine according to claim 9, it is characterised in that:Suppression medicine and the cancer therapy drug or
Anti-inflammatory drug is used in combination.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710023981.5A CN106727500A (en) | 2017-01-13 | 2017-01-13 | The application of dihydroartemisinine, suppression medicine and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710023981.5A CN106727500A (en) | 2017-01-13 | 2017-01-13 | The application of dihydroartemisinine, suppression medicine and its application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106727500A true CN106727500A (en) | 2017-05-31 |
Family
ID=58948141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710023981.5A Pending CN106727500A (en) | 2017-01-13 | 2017-01-13 | The application of dihydroartemisinine, suppression medicine and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106727500A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205292A (en) * | 2019-05-07 | 2019-09-06 | 吉林省海创生物科技有限公司 | A kind of Activation In Vitro amplification method of Human plactnta source NK cell |
CN111617070A (en) * | 2019-06-11 | 2020-09-04 | 中国农业大学 | Application of dihydroartemisinin in the preparation of medicine for treating inflammation caused by virulence protein of Streptococcus suis |
CN114668758A (en) * | 2021-05-17 | 2022-06-28 | 澳门大学 | Application of artemisinin and its derivatives in the preparation of ChAT activity enhancers |
CN115029308A (en) * | 2022-07-30 | 2022-09-09 | 广州高华生物科技有限公司 | Stem cell exosome preparation and preparation method and application thereof |
-
2017
- 2017-01-13 CN CN201710023981.5A patent/CN106727500A/en active Pending
Non-Patent Citations (1)
Title |
---|
LIFENG JIA等: "Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling", 《PLOS ONE》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205292A (en) * | 2019-05-07 | 2019-09-06 | 吉林省海创生物科技有限公司 | A kind of Activation In Vitro amplification method of Human plactnta source NK cell |
CN110205292B (en) * | 2019-05-07 | 2023-02-07 | 吉林省海创生物科技有限公司 | In-vitro activation and amplification method of human placenta-derived NK cells |
CN111617070A (en) * | 2019-06-11 | 2020-09-04 | 中国农业大学 | Application of dihydroartemisinin in the preparation of medicine for treating inflammation caused by virulence protein of Streptococcus suis |
CN114668758A (en) * | 2021-05-17 | 2022-06-28 | 澳门大学 | Application of artemisinin and its derivatives in the preparation of ChAT activity enhancers |
CN115029308A (en) * | 2022-07-30 | 2022-09-09 | 广州高华生物科技有限公司 | Stem cell exosome preparation and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104363913B (en) | CDK8/CDK19 selective depressants and its purposes in the anti-rotation shifting of cancer and chemoprophylaxis method | |
Park et al. | Preclinical mouse models of human prostate cancer and their utility in drug discovery | |
CN106727500A (en) | The application of dihydroartemisinine, suppression medicine and its application | |
Zhang et al. | Involvement of p38/NF-κB signaling pathway in the nucleus accumbens in the rewarding effects of morphine in rats | |
Wang et al. | Herb‐Partitioned Moxibustion Regulates the TLR2/NF‐κB Signaling Pathway in a Rat Model of Ulcerative Colitis | |
CN110499263B (en) | A kind of Lactobacillus plantarum X7022 and its application | |
CN106950371B (en) | At least one of PD-L1, CDK5 and CTLA4 are preparing the purposes in tumor diagnosis kit | |
Da Silva et al. | Serotonergic neurons in the nucleus raphe obscurus are not involved in the ventilatory and thermoregulatory responses to hypoxia in adult rats | |
Fan et al. | Effect of Wumeiwan on Cytokines TNF-α, IL-6, IL-8, IL-10 and Expression of NF-κBp65 in Rats with Ulcerative Colitis | |
Yong et al. | Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways | |
CN109908369A (en) | Application of a novel circular RNA circCRKL in the treatment of prostate cancer | |
Mao et al. | Yunpi Heluo decoction attenuates insulin resistance by regulating liver miR-29a-3p in Zucker diabetic fatty rats | |
CN109044999A (en) | Hyperforine promotes white adipose milkproduct in preparation and improves the purposes in the active drug of brown fat | |
Kramp et al. | Combination radiotherapy in an orthotopic mouse brain tumor model | |
Wang et al. | Upregulation of (CXC motif) ligand 13 (CXCL13) attenuates morphine analgesia in rats with cancer-induced bone pain | |
Mao et al. | Systematical investigation of the mechanism underlying the therapeutic effect of Astragalus membranaceus in ulcerative colitis | |
CN109172557B (en) | Application of PPM-18 in inducing apoptosis of bladder cancer cells by activating intracellular reactive oxygen species | |
CN105832793A (en) | Application of artemisia scoparia extract for preparing medicine for treating pneumonia caused by streptococcus pneumonia or/and beta hemolytic streptococcus | |
CN109223801A (en) | A kind of new the killing agent of gastric cancer tumor stem cell and its application | |
CN107753143A (en) | Build the method and system of gastric lymphoma animal model | |
CN106860879B (en) | The application of GBP1 gene and its inhibitor in the drug of preparation treatment lung squamous cancer | |
CN118286219B (en) | Application of loperamide in reversing 5-fluorouracil resistance in colorectal cancer | |
CN105879033B (en) | II type antagonist of GnRH is inhibiting the application in progestational hormone drug resistance endometrial carcinoma cell proliferation | |
Luo et al. | Paeoniflorin inhibits chronic restraint stress-induced progression of hepatocellular carcinoma through suppressing norepinephrine-induced activation of hepatic stellate cells via SRC/AKT/ERK pathways | |
CN109700791B (en) | Application of neosinomenine in preparing medicine for treating benign prostatic hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
RJ01 | Rejection of invention patent application after publication |